Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 6c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.41), $0.06 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $19.22 million versus the consensus estimate of $15.37 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks